medigraphic.com

2014, Número S2

<< Anterior Siguiente >>

Rev Mex Anest 2014; 37 (S2)


Reversión de la anticoagulación en cirugía de urgencia

Galván-Talamantes Y, Carrillo-Esper R

Idioma: Español
Referencias bibliográficas: 29
Paginas: 407-413
Archivo PDF: 256.33 Kb.


RESUMEN

El manejo perioperatorio de los pacientes recibiendo terapia antitrombótica a base de antagonistas de vitamina K (AVK) o nuevos anticoagulantes orales (NACOs), representan un dilema en la práctica diaria de los anestesiólogos, ya que en múltiples circunstancias nos enfrentaremos al abordaje de tales escenarios clínicos en cirugías de urgencia. En la actualidad, millones de pacientes en todo el mundo utilizan anticoagulantes para la prevención o tratamiento de una gran variedad de entidades, principalmente de origen cardiovascular. De acuerdo con estudios epidemiológicos recientes en EUA, más de 250,000 pacientes anualmente ingresan a cirugías de urgencia bajo tales esquemas terapéuticos(1), de no tratarse de manera correcta, el riesgo potencial de sangrado es inminente, incrementando la mortalidad, por lo cual es de gran relevancia conocer las directrices y proporcionar estrategias de abordaje para el manejo perioperatorio que refleja la evidencia científica disponible.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8:884-890.

  2. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615-621.

  3. Pollack CV. Managing bleeding in anticoagulated patients in the emergency care setting. J Emerg Med. 2013;45:467-477.

  4. Wood JP, Silveira JR, Maille NM, Haynes LM, Tracy PB. Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity. Blood. 2011;117:1710-1718.

  5. Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombosis models. Arterioscler Thromb Vasc Biol. 2010;30:900-908.

  6. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-1711.

  7. Da Silva MS, Sobel M. Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg. 2002;15:256-267.

  8. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.

  9. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633-1652.

  10. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.

  11. Moll S. Letter by moll regarding article, “hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran”. Circulation. 2012;e43:e24.

  12. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible non peptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885-1889.

  13. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376-381.

  14. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127:457-465.

  15. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.

  16. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104:1078-1079.

  17. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Helek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-e88s.

  18. Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108-2129.

  19. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.

  20. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116:619-624.

  21. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarininduced coagulopathy. Int J Emerg Med. 2009;2:217-225.

  22. Van Ryn J, Litzenburger T, Schurer J. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). Circulation. 2012;126:A9928.

  23. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.

  24. Wagner F, Peters H, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109:596-605.

  25. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.

  26. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal or rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.

  27. Wilcox R, Pendleton RC, Smock KJ, Rodgers GM. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Hosp Pract. 2011;39:23-34.

  28. Lu G, Deguzman FR, Karbarz MJ, Abe K, Lee G, Luan P, et al. A specific antidote for reversal antocoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat med. 2013;19:446-451.

  29. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor xainhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-1271.




2020     |     www.medigraphic.com